ArticleAsian Pacific journal of cancer prevention : APJCP2025
Parvovirus B19, Somatic Gene Mutations, and Hematologic Malignancy Subtypes: An Analytical Study.
Article in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo examine the association between somatic mutations (NPM1, FLT3, JAK2, RARA) and parvovirus B19 infection across major subtypes of myeloid malignancies, and to evaluate its potential clinical significance.
methodsThis retrospective, qualitative, exploratory study investigated the relationship between parvovirus B19 infection and key somatic mutations (NPM1, FLT3, JAK2, RARA) across subtypes of myeloid malignancies, using real-time PCR analysis of laboratory datasets obtained from the Teaching Laboratories at Medical City in Baghdad. The study included 100 patients diagnosed with AML (n ≈ 40), MPN (n ≈ 40), and APL (n ≈ 20). B19 DNA was detected by real-time PCR, while somatic mutations were recorded as binary outcomes (NPM1, FLT3-ITD, FLT3-TKD, JAK2 V617F, RARA). Associations were tested using chi-square or Fisher's exact tests, and Pearson correlation matrices were generated to examine relationships among variables.
resultsThe study confirmed established genetic patterns: NPM1 and FLT3 mutations were found in ~30% of AML cases, JAK2 V617F in 90% of MPN cases, and RARA fusion in >95% of APL cases. Parvovirus B19 was detected in a minority of patients (≈15% AML, 10% MPN, 5% APL), with no statistically significant differences among groups (p > 0.1). No significant associations were observed between B19 infection and any specific mutation or disease subtype. Correlation analysis confirmed strong associations between NPM1/FLT3 and AML, JAK2 and MPN, and RARA and APL, while B19 infection showed weak or negligible correlations across all parameters.
conclusionThis study confirmed well-known gene-disease associations in myeloid malignancies but found no significant link between parvovirus B19 infection and specific somatic mutations or disease subtypes. These findings suggest that B19 infection may be incidental, underscoring the need for larger-scale studies to clarify its clinical relevance in patients with myeloid malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.